BrainStorm Shares Exciting News About Phase IIa Trial in ALS

Earlier this year, BrainStorm Cell Therapeutics’ Phase I/II trial was fast tracked to a Phase IIa dose-escalating trial by the Israeli Ministry of Health. The Phase IIa trial design includes 12 patients split into three cohorts that will be treated “with increasing doses” of BrainStorm’s NurOwn technology. Each group will receive both intrathecal (IT) and intramuscular (IM) injections of NurOwn. BrainStorm just announced that they have successfully treated their eighth patient in the Phase IIa trial and have recruited the final patient for the third cohort. BrainStorm estimates that all 12 patients will be treated by Fall 2013. In addition, BrainStorm just submitted safety data to their Institutional Review Board (IRB) including data from the first cohort treated in this Phase IIa study.

Earlier this year, BrainStorm Cell Therapeutics’ Phase I/II trial was fast tracked to a Phase IIa dose-escalating trial by the Israeli Ministry of Health. The Phase IIa trial design includes 12 patients split into three cohorts that will be treated “with increasing doses” of BrainStorm’s NurOwn technology. Each group will receive both intrathecal (IT) and intramuscular (IM) injections of NurOwn. BrainStorm just announced that they have successfully treated their eighth patient in the Phase IIa trial and have recruited the final patient for the third cohort. BrainStorm estimates that all 12 patients will be treated by Fall 2013. In addition, BrainStorm just submitted safety data to their Institutional Review Board (IRB) including data from the first cohort treated in this Phase IIa study.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail